Bank of New York Mellon Corp raised its position in USANA Health Sciences, Inc. (NYSE:USNA – Free Report) by 2.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,841 shares of the company’s stock after buying an additional 3,047 shares during the quarter. Bank of New York Mellon Corp owned about 0.64% of USANA Health Sciences worth $7,744,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the stock. Providence Capital Advisors LLC grew its position in USANA Health Sciences by 152.3% during the first quarter. Providence Capital Advisors LLC now owns 275 shares of the company’s stock worth $58,000 after buying an additional 166 shares in the last quarter. Altshuler Shaham Ltd purchased a new position in shares of USANA Health Sciences in the 2nd quarter worth about $27,000. US Bancorp DE boosted its holdings in shares of USANA Health Sciences by 64.3% in the 1st quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares in the last quarter. Covestor Ltd boosted its holdings in shares of USANA Health Sciences by 92.7% in the 1st quarter. Covestor Ltd now owns 927 shares of the company’s stock worth $74,000 after purchasing an additional 446 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in shares of USANA Health Sciences in the 2nd quarter worth about $69,000. 52.62% of the stock is currently owned by hedge funds and other institutional investors.
USANA Health Sciences Price Performance
USNA opened at $46.09 on Monday. The business has a 50 day simple moving average of $53.58 and a two-hundred day simple moving average of $59.87. The firm has a market capitalization of $881.70 million, a price-to-earnings ratio of 14.92, a PEG ratio of 1.30 and a beta of 0.82. USANA Health Sciences, Inc. has a one year low of $44.01 and a one year high of $69.60.
Analyst Ratings Changes
USNA has been the subject of a number of research reports. DA Davidson cut their price objective on USANA Health Sciences from $62.00 to $53.00 and set a “neutral” rating for the company in a report on Wednesday, October 25th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 29th.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.
- Five stocks we like better than USANA Health Sciences
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Transportation Stocks Investing
- MarketBeat Week in Review – 11/13 – 11/17
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.